Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Lilly is expecting another revenue rise of around 32% in 2025, and analysts are expecting it to grow its share of the GLP-1 market across diabetes and obesity (it ended 2024 with 34% compared with Novo Nordisks 63%)
Safety first: Always consult your medical provider or care team to determine the appropriate dosage for your specific treatment plan
At a Glance Medications Offered Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda Brand-Name Cost & Insurance Monthly: $25 first month promo
Both medications feature tirzepatide, a receptor agonist that targets both GIP and GLP-1 receptors
Disclaimer: This information is for general knowledge and does not constitute medical advice
Daily lessons to work on your habits
